Market research
GRANULES.NSE Granules India Limited
NSE INR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 212B
- P/E ratio
- 31.84
- Analyst target
- 919.125
- Dividend yield
- 0.0%
- Beta
- 0.14
Profile
Company facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE101D01020
- Market cap
- 212B
- P/E ratio
- 31.84
- Analyst target
- 919.125
- Dividend yield
- 0.0%
- Beta
- 0.14
About
About Granules India Limited
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), finished dosages (FDs), and peptides CDMO in India and internationally. It offers paracetamol, metformin, guaifenesin, ibuprofen, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, suspensions, and powder for oral solutions. In addition, it provides development and manufacturing solutions for peptides, peptide fragments, and amino acid derivatives. The company offers its products in various therapeutic categories, including antiretroviral, anti-depressant, antihistamine, anti-diabetic, anti-cancer, multiple sclerosis, anti-thrombocytopenia, anti-ulcer, anti-convulsant, mucolytic/expectorant, anti-hypertensive, muscle relaxant, NSAIDs, anti-fibrotic, and anti-microbial, as well as anti-arrhythmic, CNS stimulant, anti-diarrheal, antihypertensive, uterine stimulant, chelating agent, mineral supplements, CNS depressant, PDE inhibitor, antispasmodic, and anti-viral. Granules India Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the GRANULES.NSE discussion.
5 years, 4 months ago
Granules India Limited is currently in a long term downtrend where the price is trading 2.1% below its 200 day moving average.
From a valuation standpoint, the stock is 45.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.6.
Granules India Limited's total revenue rose by 20.0% to $8B since the same quarter in the previous year.
Its net income has increased by 129.3% to $1B since the same quarter in the previous year.
Finally, its free cash flow fell by 13.5% to $2B since the same quarter in the previous year.
Based on the above factors, Granules India Limited gets an overall score of 3/5.